Preventing vascular aging caused by the chemotherapy drug doxorubicin
Targeting cellular senescence to prevent accelerated vascular aging induced by the common chemotherapeutic agent doxorubicin
This study is looking at how aging and a specific cancer treatment can affect blood vessel health in older adults and cancer survivors, with the goal of finding ways to help improve their circulation and overall vascular function.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado NIH-funded |
| Lab location | 1 site (Boulder, UNITED STATES) |
| Project ID | NIH-10684719 on NIH RePORTER |
What this research studies
This research investigates how cellular senescence contributes to vascular aging, particularly in older adults and cancer survivors who have received doxorubicin chemotherapy. The study aims to understand the mechanisms behind vascular dysfunction, such as impaired blood vessel function and increased stiffness, which are exacerbated by aging and chemotherapy. By exploring the role of reactive oxygen species and nitric oxide bioavailability, the research seeks to identify potential therapeutic targets to improve vascular health in affected patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include older adults and cancer survivors who have received doxorubicin and are experiencing vascular dysfunction.
Not a fit: Patients who have not undergone chemotherapy or do not exhibit signs of vascular dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or reverse vascular aging in patients who have undergone chemotherapy.
How similar studies have performed: Previous research has shown that targeting cellular senescence can improve vascular health, suggesting that this approach may be effective in this context as well.
Where this research is happening
Boulder, UNITED STATES
- University of Colorado — Boulder, United States (Active)
Researchers
- Principal investigator: Seals, Douglas R — University of Colorado
- Study coordinator: Seals, Douglas R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.